These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15011600)

  • 21. AIDS could dominate Russian budget by 2020.
    Walgate R
    Bull World Health Organ; 2002; 80(8):686-7. PubMed ID: 12219165
    [No Abstract]   [Full Text] [Related]  

  • 22. [HIV associated encephalopathy after highly active antiretroviral therapy (HAART)].
    Kishida S
    No To Shinkei; 2004 Apr; 56(4):301-10. PubMed ID: 15237721
    [No Abstract]   [Full Text] [Related]  

  • 23. Treating HIV. On-and-off therapy works--and cuts costs too.
    Nursing; 2002 Feb; 32(2):33. PubMed ID: 11924163
    [No Abstract]   [Full Text] [Related]  

  • 24. AIDS--will the next 20 years be different?
    Steinbrook R; Drazen JM
    N Engl J Med; 2001 Jun; 344(23):1781-2. PubMed ID: 11396446
    [No Abstract]   [Full Text] [Related]  

  • 25. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brazil shares blueprint of successful battle against HIV/AIDS.
    AIDS Policy Law; 2002 Aug; 17(16):7. PubMed ID: 12236218
    [No Abstract]   [Full Text] [Related]  

  • 28. Balancing effectiveness and access to HIV treatment in the developing world.
    Hill A; Wood E
    AIDS; 2007 Jan; 21(3):361-3. PubMed ID: 17255743
    [No Abstract]   [Full Text] [Related]  

  • 29. Socio-economic impact of antiviral intervention.
    Flessa S; Marschall P
    Handb Exp Pharmacol; 2009; (189):347-74. PubMed ID: 19048207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HAART for hospital health care workers--an innovative programme.
    Uebel K; Friedland G; Pawinski R; Holst H
    S Afr Med J; 2004 Jun; 94(6):423-7. PubMed ID: 15250450
    [No Abstract]   [Full Text] [Related]  

  • 31. Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence.
    Gaitan Cepeda LA; Ceballos Salobreña A; López Ortega K; Arzate Mora N; Jiménez Soriano Y
    Med Oral Patol Oral Cir Bucal; 2008 Feb; 13(2):E85-93. PubMed ID: 18223535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An emerging severe leukoencephalopathy: is it due to HIV disease or highly active antiretroviral therapy?
    Rackstraw S; Meadway J; Bingham J; Al-Sarraj S; Everall I
    Int J STD AIDS; 2006 Mar; 17(3):205-7. PubMed ID: 16510013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.
    Antinori A; Larussa D; Cingolani A; Lorenzini P; Bossolasco S; Finazzi MG; Bongiovanni M; Guaraldi G; Grisetti S; Vigo B; Gigli B; Mariano A; Dalle Nogare ER; De Marco M; Moretti F; Corsi P; Abrescia N; Rellecati P; Castagna A; Mussini C; Ammassari A; Cinque P; d'Arminio Monforte A;
    Clin Infect Dis; 2004 Dec; 39(11):1681-91. PubMed ID: 15578371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).
    Gazzard B;
    HIV Med; 2005 Jul; 6 Suppl 2():1-61. PubMed ID: 16011536
    [No Abstract]   [Full Text] [Related]  

  • 35. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
    Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute megakaryoblastic leukemia in a patient receiving HAART.
    Larussa D; Grisetti S; Pilozzi E; Concorsi P; Pisa R; Ruco L; Antinori A
    Am J Hematol; 2005 Sep; 80(1):89-90. PubMed ID: 16138353
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordant responses to HAART in HIV-1 patients: the need to focus on intervention.
    De Maria A
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):523-7. PubMed ID: 17678414
    [No Abstract]   [Full Text] [Related]  

  • 39. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment.
    Gray F; Bazille C; Adle-Biassette H; Mikol J; Moulignier A; Scaravilli F
    J Neurovirol; 2005; 11 Suppl 3():16-22. PubMed ID: 16540449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cash invigorates European AIDS study.
    Dickson D
    Nat Med; 2001 May; 7(5):516. PubMed ID: 11329032
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.